Proportion of estrogen or progesterone receptor expressing cells in breast cancers and response to endocrine therapy.

[1]  A. Thompson,et al.  Progesterone receptor expression is an independent prognostic variable in early breast cancer: a population-based study , 2013, British Journal of Cancer.

[2]  M. Dowsett,et al.  Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[3]  R Peto,et al.  Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials , 2011, The Lancet.

[4]  R. Gelber,et al.  Strategies for subtypes—dealing with the diversity of breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011 , 2011, Annals of oncology : official journal of the European Society for Medical Oncology.

[5]  Anthony Rhodes,et al.  American Society of Clinical Oncology/College of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer. , 2010, Archives of pathology & laboratory medicine.

[6]  R. Gelber,et al.  Thresholds for therapies: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2009 , 2009, Annals of oncology : official journal of the European Society for Medical Oncology.

[7]  R. Gelber,et al.  Re-evaluating adjuvant breast cancer trials: assessing hormone receptor status by immunohistochemical versus extraction assays. , 2006, Journal of the National Cancer Institute.

[8]  D. Allred,et al.  Progesterone receptor by immunohistochemistry and clinical outcome in breast cancer: a validation study , 2004, Modern Pathology.

[9]  Tadashi Hasegawa,et al.  Evaluation of the Interobserver Agreement in the Number of Mitotic Figures Breast Carcinoma as Simulation of Quality Monitoring in the Japan National Surgical Adjuvant Study of Breast Cancer (NSAS‐BC) Protocol , 2000, Japanese journal of cancer research : Gann.

[10]  C K Osborne,et al.  Estrogen receptor status by immunohistochemistry is superior to the ligand-binding assay for predicting response to adjuvant endocrine therapy in breast cancer. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[11]  H. Tsuda,et al.  Establishment of histological criteria for high-risk node-negative breast carcinoma for a multi-institutional randomized clinical trial of adjuvant therapy. Japan National Surgical Adjuvant Study of Breast Cancer (NSAS-BC) Pathology Section. , 1998, Japanese journal of clinical oncology.

[12]  Early Breast Cancer Trialists' Collaborative Group.  Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy 133 randomised trials involving 31 000 recurrences and 24 000 deaths among 75 000 women , 1992, The Lancet.

[13]  E. Milgrom,et al.  Characterization of the hormone responsive element involved in the regulation of the progesterone receptor gene. , 1991, The EMBO journal.

[14]  C. Redmond,et al.  Influence of tumor estrogen and progesterone receptor levels on the response to tamoxifen and chemotherapy in primary breast cancer. , 1983, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[15]  C. Redmond,et al.  Treatment of primary breast cancer with chemotherapy and tamoxifen. , 1981, The New England journal of medicine.

[16]  W. McGuire,et al.  Predicting response to endocrine therapy in human breast cancer: a hypothesis. , 1975, Science.

[17]  Early Breast Cancer Trialists' Collaborative Group.  Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy. 133 randomised trials involving 31,000 recurrences and 24,000 deaths among 75,000 women. Early Breast Cancer Trialists' Collaborative Group. , 1992, Lancet.

[18]  B. Djulbegovic,et al.  Comparison of sex steroid receptor determinations in human breast cancer by enzyme immunoassay and radioligand binding , 1990, Journal of clinical laboratory analysis.